EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma

On August 25, 2020, a marketing authorization valid through the European Union was issued for belantamab mafodotin monotherapy for the treatment of multiple myeloma (MM) in adult patients who have received at least four prior therapies, whose disease is refractory to at least one proteasome inhibito...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncologist
Huvudupphovsmän: Tzogani, Kyriaki, Penttilä, Karri, Lähteenvuo, Johanna, Lapveteläinen, Tuomo, Lopez Anglada, Lucía, Prieto, Carolina, Garcia‐Ochoa, Blanca, Enzmann, Harald, Gisselbrecht, Christian, Delgado, Julio, Pignatti, Francesco
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley & Sons, Inc. 2020
Ämnen:
Regulatory Issues: EMA
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7794172/
https://ncbi.nlm.nih.gov/pubmed/33179377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13592
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk